http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2029419-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d0446a5bd77c7da68216fc2e3f05d48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f84747e8d08b1023763356d0e7d1db68 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 |
| filingDate | 1990-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eff60ce69e5f5219a18223c730540f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7439f94b6b914991b33eb80c8d689632 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0834a7bee8eaa08f1b51b7498d0492af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac4affa96cc6bd65e77a36553d986b11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c17d8961be06a04b3b3cc3a272e2455 |
| publicationDate | 2004-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2029419-C |
| titleOfInvention | Nmda-blocking pharmaceutical compositions |
| abstract | The present invention relates to pharmaceutical compositions for preventing excitatory amino acids neurotoxicity comprising as active ingredient (3S,4S)-tetrahydrocannabinol (THC) type compounds of general formula (I), as hereunder defined. The compositions of the present invention are particularly effective in alleviating and even preventing glutamate neurotoxicity due to acute to the central nervous system (CNS), such as injuries due to prolonged seizures, compromised or reduced blood supply, deprivation of glucose supply and mechanical trauma. The present compositions may also be effective in alleviating other damages to the CNS like poison-induced convulsions, considered to be associated with amino acids receptors other than that of glutamate, for example glycine. The compositions of the present invention are also effective in the treatment of certain chronic degenerative diseases which are characterized by gradual selective neuronal loss. In this connection, the compositions of the present invention are contemplated as therapeutically effective in the treatment of the Alzheimer's disease. The present compositions are of special value in grand mal seizures, global hypoxic ischemic insults, in hypoxia, alone or in combination with blood flow reduction (ischemia) as well as in cases of cardiac arrest and in cases of abrupt occlusion of cerebral arteries (stroke). Some of the compounds according to formula (I), as will be hereinafter described in detail, are novel compounds and are claimed as such within the scope of the present application. The active ingredient of the pharmaceutical compositions according to the present invention is a compound of the general formula; having the (+)-(3S,4S) configuration, wherein A----B designates a 1(2) or a 6(1) double bond, R designates CH3 or CH2OH, R1 designates a hydrogen atom or a lower acyl group, and R2 designates (A) a straight-chained or branched C6-12alkyl radical; or (B) a group -O-R3, in which R3 is a straight-chained or branched C5-9alkyl radical or a straight-chained or branched alkyl radical substituted at the terminal carbon atom by a phenyl group. Compounds of formula (I) in which R designates CH2OH and R1 designates a lower acyl group are novel compounds. |
| priorityDate | 1989-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.